Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May;23(5):795-804.
doi: 10.1016/j.bbmt.2017.02.009. Epub 2017 Feb 14.

Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source

Sharat Damodar  1 , Ryan Shanley  2 , Margaret MacMillan  2 , Celalettin Ustun  2 , Daniel Weisdorf  3
Affiliations

Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source

Sharat Damodar et al. Biol Blood Marrow Transplant. 2017 May.

Abstract

The impact of ABO mismatch has been studied on various hematopoietic cell transplant (HCT) outcomes, including neutrophil and platelet engraftment, pure red cell aplasia, acute and chronic graft-versus-host disease (GVHD), nonrelapse mortality (NRM), and overall survival (OS). Yet conflicting results have been reported. However, the impact of ABO mismatch on transplant outcomes with various graft types has not been carefully investigated. We analyzed the impact of various graft sources and type of ABO mismatch on transplant outcomes for 1502 patients who underwent HCT at the University of Minnesota between 2000 and 2014: 312 receiving marrow (BM), 475 filgrastim-mobilized blood (peripheral blood stem cell [PBSC]), and 715 umbilical cord blood (UCB) grafts. Neutrophil engraftment by day 28 was marginally less frequent in the bidirectional ABO mismatched transplants receiving UCB, whereas ABO matching had no influence on engraftment in the BM or PBSC cohorts. ABO mismatch led to no significant differences in platelet engraftment irrespective of stem cell source. We observed a modest but not significantly lower incidence of grades II/IV acute GVHD in the bidirectional ABO mismatched transplants in the UCB and the PBSC cohorts but not in the BM group. We found a higher incidence of chronic GVHD in the PBSC group, but it was not significantly lower in the minor ABO mismatched transplants. The incidence of chronic GVHD was similar in the major ABO mismatched transplants receiving BM. We found no significant difference in the OS and NRM between ABO matched and ABO mismatched transplants within each of the 3 graft source groups. Multivariable analysis adjusting for other relevant factors confirmed that ABO match status did not significantly influence the outcomes of either engraftment, acute or chronic GVHD or NRM. We conclude that ABO mismatch does not influence the outcomes of allogeneic HCT, regardless of stem cell source.

Keywords: ABO incompatibility; ABO mismatched HCT; Graft source; Transplant.

PubMed Disclaimer

Figures

Fig 1
Fig 1. GVHD and survival by Graft source and ABO match
Shown are the incidence of Acute GVHD grade II–IV and Survival for the ABO matching groups within each of the 3 graft types analyzed. There are no significant differences in either GVHD (p=0.10, 0.74, 0.60 for UCB, PBSC, BM, per the multivariate analysis Table 3A), or Survival (p=0.29, 0.92, 0.64, respectively).
Fig 1
Fig 1. GVHD and survival by Graft source and ABO match
Shown are the incidence of Acute GVHD grade II–IV and Survival for the ABO matching groups within each of the 3 graft types analyzed. There are no significant differences in either GVHD (p=0.10, 0.74, 0.60 for UCB, PBSC, BM, per the multivariate analysis Table 3A), or Survival (p=0.29, 0.92, 0.64, respectively).
Fig 1
Fig 1. GVHD and survival by Graft source and ABO match
Shown are the incidence of Acute GVHD grade II–IV and Survival for the ABO matching groups within each of the 3 graft types analyzed. There are no significant differences in either GVHD (p=0.10, 0.74, 0.60 for UCB, PBSC, BM, per the multivariate analysis Table 3A), or Survival (p=0.29, 0.92, 0.64, respectively).
See this image and copyright information in PMC

References

    1. Dunstan RA. Status of major red cell blood group antigens on neutrophils, lymphocytes and monocytes. Br J Haematol. 1986;62:301–309. - PubMed
    1. Cooling LLW, Kelly K, Barton J, Hwang D, Koerner TAW, Olson JD. Determinants of ABH expression on human blood platelets. Blood. 2005;105:3356–3364. - PubMed
    1. Kimura F, Sato K, Kobayashi S, Ikeda T, Sao H, Okamoto S, Miyamura K, Mori S, Akiyama H, Hirokawa M, Ohto H, Ashida H, Motoyoshi K Japan Marrow Donor P. Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program. Haematologica. 2008;93:1686–1693. - PubMed
    1. Kollman C, Howe CWS, Anasetti C, Antin JH, Davies SM, Filipovich AH, Hegland J, Kamani N, Kernan NA, King R, Ratanatharathorn V, Weisdorf D, Confer DL. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98:2043–2051. - PubMed
    1. Michallet M, Le QH, Mohty M, Prebet T, Nicolini F, Boiron JM, Esperou H, Attal M, Milpied N, Lioure B, Bordigoni P, Yakoub-Agha I, Bourhis JH, Rio B, Deconinck E, Renaud M, Chir Z, Blaise D. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et deThérapie Cellulaire. Exp Hematol. 2008;36:535–544. - PubMed

MeSH terms

Substances

LinkOut - more resources